How to appeal a Humana autoimmune cytopenias (itp + aiha) denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for autoimmune cytopenias (itp + aiha)

Cited policy: Humana Rituximab (Rituxan) for ITP and AIHA — Off-Label

ITP — chronic or persistent with insufficient response to >=1 prior therapy. Warm AIHA — steroid-refractory or steroid-dependent (>10-20 mg/d prednisone to maintain Hgb). Cold AIHA — symptomatic hemolysis. Standard dosing 375 mg/m2 IV weekly x 4 (or 1000 mg x 2 some protocols). Hep B screen + vaccinations updated. Hematologist Rx.

How Humana denies autoimmune cytopenias (itp + aiha) — and how to counter it

Where Humana pushes back: 1) Off-label for ITP / AIHA; 2) Insufficient evidence; 3) Not FDA-approved for this indication.

Counter-arguments that hold up: Rituximab is OFF-LABEL but evidence-based standard-of-care for ITP and AIHA. ASH 2019 ITP Guideline (Neunert Bloodadv 2019) recommends rituximab as a parallel second-line option alongside TPO-RA and splenectomy. ICR 2019 (Provan) endorses same. BSH AIHA 2017 (Hill BJH 2017;176:395-411) lists rituximab + steroids as preferred second-line for warm AIHA. Hill 2024 international consensus endorses rituximab for cold AIHA. Pivotal evidence — Birgens BJH 2013 RIWAR (rituximab + prednisone vs prednisone alone in warm AIHA, response 75% vs 36%); Khellaf Blood 2014 French ITP registry; Arnold Ann Intern Med 2007 systematic review. Insurance must cover medically-necessary off-label use per state external-review mandates and ACA federal external-review process. Off-label status is NOT a permissible denial basis when use is supported by peer-reviewed compendia (NCCN, AHFS DI, DrugDex).

What Humana typically denies for autoimmune cytopenias (itp + aiha)

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For autoimmune cytopenias (itp + aiha), expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the autoimmune cytopenias (itp + aiha) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Steroids (pred / dex)
• IVIG
• Anti-D (WinRho)
• Rituximab (off-label)
• Promacta (eltrombopag)
• Nplate (romiplostim)

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.